The $6.3 billion global next-generation sequencing (NGS) market is expected to increase at a substantial pace of 16% by 2026.

Health
Tony KingLeave a Comment on The $6.3 billion global next-generation sequencing (NGS) market is expected to increase at a substantial pace of 16% by 2026.

Rapid developments in sequencing platforms, growing applications of NGS, demand for NGS services, development of advanced bioinformatics tools, high investments in R&D, and growing number of cancer and infectious diseases are some of the key factors driving the market’s growth.

Next-generation sequencing is a technique for determining the sequence of DNA or RNA in order to investigate genetic variations linked to diseases or other biological phenomena. NGS refers to a set of technologies that use massively parallel sequencing to generate millions of short read sequences in a shorter time and with considerably higher throughput.

Find A Free Sample of Our Report @ https://meditechinsights.com/next-generation-sequencing-ngs-market/request-sample/

Technological advancements in sequencing platforms to fuel its high demand

Continuous advances in sequencing technology have enabled to develop efficient, portable, and easy-to-use NGS sequencers to deliver rapid and precise results while also reducing turnaround times. Such advancements tend to provide competitive edge to manufacturers and therefore, major players are continuously focusing on investing in research activities for new product development to strengthen their positions in this high growth market. Some of the technological advancements are listed below:

  • In March 2022, Element Biosciences Inc. launched its benchtop sequencer – Element AVITI System, that offers combination of performance, cost, and flexibility in an unprecedented way. This system consists of a benchtop NGS instrument and related consumables
  • In December 2021, Singular Genomics Systems, Inc. commercially launched its G4 platform, a powerful benchtop sequencer featuring a new high-performance chemistry with advanced engineering to give precision, flexibility, speed, and power for a wide range of applications, including cancer and immunology research
  • In December 2021, Roche launched its AVENIO Edge System, a next-generation platform to assist sequencing laboratories and researchers to reduce human error, further providing fast, precise, and reliable results
See also  The Contrast Media Market Envisions Steady Expansion: Projecting a 5-6% CAGR.

Partnership and collaboration to boost adoption and research outcomes for diagnostic applications

The next-generation sequencing market has witnessed a number of partnerships and collaborations by market players to enhance the adoption of this technology for clinical applications and co-develop advanced diagnostic solutions. Some of the strategic initiatives that boost the adoption of NGS for diagnostic applications are listed below:

  • In January 2022, Illumina entered into multi-year partnership with Agendia N.V., a precision oncology provider for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing using NGS technology
  • In July 2021, Qiagen partnered with Sysmex for the development and marketing of cancer companion diagnostic (CDx) solutions, leveraging Sysmex’s Plasma-Safe-SeqS technology for NGS
  • In April 2021, Thermo Fisher Scientific collaborated with Mayo Clinic, a non-profit organisation to accelerate access to innovative diagnostic solutions for haematology, allergy, oncology, and autoimmunity diagnostics, leveraging NGS technology
  • In January 2021, Illumina announced precision oncology partnerships with Merck, Bristol Myers Squibb, Myriad Genetics, and Kura Oncology for advancements in comprehensive genomic profiling using TruSight Oncology product portfolio
  • In August 2020, Oxford Nanopore Technologies entered into an agreement with the UK’s Department of Health and Social Care, to roll out its LamPORE SARS-CoV-2 tests across NHS testing laboratories
See also  Global Urology Devices Market Overview The global urology devices market is poised for steady expansion and is projected to grow at a CAGR of approximately 6–7% during the forecast period from 2024 to 2029. This growth trajectory is primarily driven by the rising prevalence of urological disorders and urological cancers across both developed and developing regions. Key Request a free sample copy or view report summary: https://meditechinsights.com/urology-devices-market/request-sample/ An increasing global geriatric population is significantly contributing to market growth, as aging individuals are more prone to conditions such as benign prostatic hyperplasia, urinary incontinence, kidney stones, and bladder dysfunction. Advancements in urology treatment modalities and medical technologies are enabling more accurate diagnosis and effective treatment of complex urological conditions. Despite positive growth prospects, the high initial cost associated with advanced urology equipment and the shortage of skilled urologists in certain regions may restrain market expansion to some extent. Definition and Scope of Urology Devices Urology devices comprise a broad range of medical instruments and equipment used for the diagnosis, monitoring, and treatment of disorders affecting the urinary tract and male reproductive system. These devices are widely utilized in hospitals, specialty clinics, ambulatory surgical centers, and urology practices. Common urology devices include endoscopes, catheters, laser systems, lithotripters, robotic surgical systems, and various surgical instruments. Urology devices play a critical role in managing conditions such as kidney stones, prostate cancer, urinary incontinence, erectile dysfunction, and bladder disorders. Continuous innovation in this field is improving procedural efficiency, patient comfort, and clinical outcomes. Shift Toward Minimally Invasive Urological Procedures The urology devices market is witnessing a strong shift toward minimally invasive surgical procedures. Minimally invasive techniques offer significant advantages, including reduced hospital stays, shorter recovery times, and lower risk of post-operative complications. Procedures such as laparoscopic and robotic-assisted surgeries are becoming increasingly common in urology practices. Endoscopic devices and laser-based technologies are widely used for stone removal, prostate treatments, and tumor ablation. The growing preference for minimally invasive approaches is driving demand for advanced urology devices with enhanced precision and control. Integration of Digital Technologies in Urology Digital transformation is playing an increasingly important role in the evolution of the urology devices market. The integration of artificial intelligence is enhancing diagnostic accuracy and supporting clinical decision-making in urology procedures. Advanced imaging systems provide real-time visualization, enabling urologists to perform complex procedures with greater confidence. Telemedicine solutions are improving patient access to urology consultations, particularly in remote and underserved regions. Digital platforms are also enabling better treatment planning, patient monitoring, and post-procedure follow-up. Technological Advancements Driving Market Growth Rapid technological advancements are a key factor fueling growth in the urology devices market. Innovations in robotics have significantly improved the precision of procedures such as prostatectomy and nephrectomy. Robotic-assisted urological surgeries allow for enhanced dexterity, improved visualization, and greater surgical accuracy. Laser technologies used in lithotripsy and soft tissue ablation are becoming more efficient and safer for patients. Enhanced imaging systems and navigation technologies are reducing procedural risks and improving overall outcomes. Impact of Aging Population on Urology Device Demand The aging global population is a major driver of demand for urology devices. Older adults are more susceptible to urological conditions due to physiological changes and age-related degeneration. Benign prostatic hyperplasia is highly prevalent among elderly men and often requires long-term management or surgical intervention. Urinary incontinence and bladder dysfunction are also common among aging populations, increasing the need for diagnostic and therapeutic devices. As life expectancy continues to rise, the demand for urology devices is expected to grow steadily. Rising Incidence of Urological Disorders The prevalence of urological disorders is increasing globally, contributing significantly to market growth. Lifestyle-related factors such as obesity, diabetes, smoking, and poor dietary habits are increasing the risk of urological diseases. Kidney stones are becoming more common due to changes in diet and fluid intake patterns. Rising incidence of prostate and bladder cancers is driving demand for advanced diagnostic and treatment devices. Early diagnosis and effective management of these conditions rely heavily on modern urology devices. Growth Opportunities in Emerging Markets Emerging markets are expected to offer significant growth opportunities for the urology devices market. Rapid urbanization and improving healthcare infrastructure are enhancing access to specialized urological care. Governments in emerging economies are increasing investments in healthcare modernization and medical equipment procurement. Rising awareness of urological health and availability of trained specialists are further supporting market expansion. The growing middle-class population and increasing healthcare expenditure are driving demand for advanced urology devices in these regions. Challenges Limiting Market Expansion High acquisition and maintenance costs of advanced urology devices pose a challenge for healthcare providers, particularly in resource-limited settings. Limited availability of skilled urologists and trained technicians can restrict the adoption of sophisticated technologies. Regulatory approval processes and compliance requirements may increase time-to-market for new devices. Reimbursement constraints in certain healthcare systems may limit patient access to advanced urology procedures. Impact of Private Equity Investment in Urology Practices Private equity investment is emerging as an important growth catalyst within the urology devices market. Financial backing from private equity firms enables urology practices to improve operational efficiency and expand service offerings. Access to capital allows practices to invest in advanced urology devices and cutting-edge technologies. Private equity involvement supports consolidation and modernization of fragmented urology practices. Between January 2018 and 2022, only 26 urology-related private equity deals were recorded, indicating significant untapped consolidation potential. In comparison, other specialties such as dermatology, orthopedics, gastroenterology, and cardiology have seen substantially higher deal activity. A large proportion of practicing urologists are nearing retirement age, creating opportunities for private equity-led acquisitions. According to the American Urological Association, more than 55% of private practice urologists were aged 65 or older in 2022. Private equity deals offer retiring physicians the option to maintain ownership stakes while transitioning out of clinical practice. Competitive Landscape Analysis The global urology devices market is highly competitive, with the presence of established multinational corporations and specialized medical device companies. Leading players focus on continuous innovation, product differentiation, and portfolio expansion to maintain competitive advantage. Strategic acquisitions and mergers are commonly used to strengthen market presence and expand technological capabilities. Partnerships with healthcare providers and research institutions support product development and clinical validation. New product launches targeting minimally invasive and digitally integrated solutions are shaping competitive dynamics. Future Outlook of the Urology Devices Market The urology devices market is expected to witness sustained growth driven by technological innovation and increasing disease burden. Ongoing advancements in robotics, imaging, and digital health will continue to transform urological care. Replacement demand and technology upgrades will support steady growth in developed markets. Emerging economies will present strong expansion opportunities due to improving healthcare access and rising patient awareness. Overall, the global urology devices market offers attractive long-term growth potential supported by demographic trends, innovation, and expanding clinical applications. Key Players in the Global Urology Devices Market •Boston Scientific Corporation •Medtronic •Coloplast •Baxter International •Becton Dickinson •Stryker Corporation •Olympus Corporation •ConvaTec •B. Braun Melsungen AG •Fresenius Medical Care Get Free Sample Report: https://meditechinsights.com/urology-devices-market/request-sample/ About Medi-Tech Insights Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers

Expensive platforms and experimental challenges – Limiting Next-generation Sequencing Market Growth

Although NGS technology offers multiple advantages, it has certain implementation challenges which affect its adoption among low- and mid-income countries. These include high cost of sequencers, dearth of trained and skilled technicians, ethical and legal limitations, and lack of genetic counselling guidelines.

  • High cost of sequencers: High-end sequencers from Illumina and PacBio are priced over $950k and $450k respectively which represent a large capital expenditure for most labs. When it comes to the procurement and usage of innovative and high-priced NGS equipment and technologies, numerous research and academic institutes face budget limits. As a result, innovative research facility construction and expansion in academic and research institutes in underdeveloped countries is restricted
  • Dearth of trained and skilled technicians: Technicians with the necessary abilities and experience, as well as computational and IT infrastructure are required, to facilitate the analysis of huge amounts of data generated by NGS. Bioinformatics/data analysis, on the other hand, is a big barrier for many clinical laboratories due to the data-intensive nature of NGS. In small- to mid-size clinical laboratories, it is difficult to recruit and retain critical NGS bioinformatics personnel due to shortage of expert technicians/bioinformaticians
  • Ethical and legal limitations: With technological advancements and increase in avenues for accessing personal data, addressing privacy risks has become more difficult. For these reasons, the use of next-generation sequencing (NGS) in research and clinical settings has raised concerns about data protection, informed consent, and the return of results
  • Lack of genetic counselling guidelines: The interpretation of NGS data is becoming increasingly widespread, necessitating the formation of a multidisciplinary team that includes a well-trained genetic counsellor. Counselling and testing for single gene disorders is very simple, however, heterogenous genetic disorders such as glutaric aciduria type I (GA1), Canavan Disease, cancer, and neuromuscular problems are complex and require proper guidelines.
See also  Allergy Treatment Market to grow 6–7% CAGR supported by early detection technologies by 2029

With the sequencing costs falling down considerably over the last few years, platform manufacturers have developed and commercialized low-cost sequencers to increase adoption among large- and budget-conscious laboratories. For instance, GridION nanopore-based sequencer offered by Oxford Nanopore Technologies is priced at $49k. Furthermore, use of Big Data approaches to data collection and analysis, as well as trends toward increased data sharing, have created challenges for providing adequate information to patients and researchers about how their data may be shared and used, while also maintaining privacy protections.

Competitive Landscape Analysis: Next-generation Sequencing Market

The Next-generation Sequencing (NGS) market is marked by the presence of key players such as Illumina (US), Thermo Fisher Scientific (US), Pacific Biosciences (US), Oxford Nanopore Technologies (UK),Hoffmann-La Roche AG (Switzerland), QIAGEN (Germany), and others.

Related Posts

Stem Cells Market Depth Study, Analysis, Key Drivers, Top Players, Trends and Forecast 2031

MediTech

Long-Term Care Software Market 2026 | Demand for Evidence Based Medicine and Research Updates

MediTech

Platelet Rich Plasma (PRP) Market Size, Share and Manufacture Development Analysis by 2026-2031

MediTech

Leave a Reply